Publications by authors named "Shuainan Lin"
Background: Lecanemab, a novel monoclonal antibody targeting amyloid-β, has shown promise in treating Alzheimer's disease. Comprehensive post-marketing safety data analysis is crucial to understand its real-world risk profile.
Objective: This study aimed to evaluate the safety profile of lecanemab using data from the FDA Adverse Event Reporting System (FAERS), with a focus on nervous system disorders and amyloid-related imaging abnormalities.
Article Synopsis
- Osteonecrosis of the jaw (ONJ) is a serious risk associated with bisphosphonate treatment, particularly zoledronic acid, used for conditions like osteoporosis and bone metastasis, prompting the development of a predictive model for its occurrence.
- The study utilized data from the FDA Adverse Event Reporting System and the Canada Vigilance Adverse Reaction database to identify factors predicting ONJ in patients treated with zoledronic acid, applying logistic regression and nomogram analysis for model construction.
- Results revealed significant predictors for ONJ, including bone metastasis, osteoporosis, medication count, and zoledronic acid dosage, with the predictive model demonstrating strong performance in distinguishing patients at high risk of ONJ.
Background: The cyclooxygenase-2 (COX-2) selective inhibitor parecoxib is widely used in the treatment of pain and inflammation. Parecoxib has been adopted for use for postoperative analgesia following a range of surgical procedures (orthopedic, general, gynecological, and dental surgery). Total knee or total hip arthroplasty (THA) surgery is mostly done in older patients, so postoperative analgesics need to be used more carefully, and the safety and efficacy of parecoxib in this type of surgery need to be further verified.
View Article and Find Full Text PDF